Zevorcabtagene Autoleucel
PreclinicalCell therapy
Zevorcabtagene Autoleucel is one of 38 small molecule programs targeting Multiple Myeloma. It is currently in Preclinical.
1
Indications
2
Total Trials
2
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
282 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Xpovio
KKaryopharm Therapeutics Inc
Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Treanda
AAzurity Pharmaceuticals
Phase 3
Neulasta
AmgenPhase 3
Vepesid
AAvyxa
Phase 3
Cytosar
TevaPhase 3
Busulfex
Akero TherapeuticsPhase 3
BLENREP
GGlaxo Dba Glaxosmithkline
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Zevorcabtagene Autoleucel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Preclinical[1]
- Company
- CCARsgen Therapeutics Co., Ltd.